IC 303-2023: 'Hype, Promise, and Reality: Orthopedic Use of Biologics in 2023'-IC 303 - 'Hype, Promise, and Reality: Orthopedic Use of Biologics in 2023' (1/5)

IC 303 - 'Hype, Promise, and Reality: Orthopedic Use of Biologics in 2023' (1/5)

Video Transcription

Video Summary

In this video, the speaker discusses the growing market for orthopedic treatments, specifically for knee osteoarthritis. They highlight the opportunity to increase income through new treatment modalities as the number of patients with osteoarthritis is expected to double in the next 20 years. The speaker also provides information on billing for orthobiologics, such as inter-articular corticosteroids, hyaluronic acid, PRP (platelet-rich plasma), microfragmented fat, and BMAC (bone marrow aspirate concentrate). They explain the specific coding and billing guidelines for each treatment and emphasize the importance of informed consent and documentation. The speaker also acknowledges the need for transparency, adherence to FDA regulations, and proper patient education.

Asset Caption

Louis McIntyre, MD

Keywords

orthopedic treatments

knee osteoarthritis

income increase

treatment modalities

billing for orthobiologics